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Abstract: Normal thymic architecture is essential for the proper 
development of T-lymphocytes. Immature T-cell progenitors enter 
the thymus where through interactions with cortical and medullary 
thymic epithelial cells (TECs) they undergo positive and negative 
selection and become competent cells that do not react with self-anti-
gens. This process requires normal thymic architecture, expression 
of major histocompatibility complex (MHC) class II, and normal 
expression of the autoimmune regulator (AIRE) gene. Thymomas 
are rare neoplasms of the TECs that often generate lymphocytes 
that mature into CD4+ and CD8+ T-lymphocytes. However, sev-
eral abnormalities have been described in thymomas that may affect 
normal T-cell development: the tumor architecture is distorted, neo-
plastics expresses less MHC class II, most thymomas do not express 
AIRE, and production of T-regulator cells is decreased. Thymomas 
are associated with a variety of autoimmune disorders often linked 
to T–cell-mediated autoimmunity. Myasthenia gravis, the most com-
mon autoimmune disorder associated with thymoma patients, is pres-
ent in 30% of patients with thymoma. Several theories attempt to 
explain the association of immune disorders with thymomas. These 
different theories are based on failure of positive and negative selec-
tion of T-lymphocytes and on autoimmunizing mechanisms in an 
AIRE-poor environment in the thymus. The finding that immunosur-
veillance against cancer may be impaired before the diagnosis of thy-
moma may challenge current theories and suggest a more complex 
defect in T-lymphocyte maturation. It is likely that a combination of 
mechanisms is responsible for immune disorders in patients with thy-
moma. More investigation is needed to clarify the basic mechanisms 
responsible for immune disorders in patients with thymoma.
Key Words: Thymoma, Immunology, Autoimmune disorders, Thymic 
carcinoma, Thymus.
(J Thorac Oncol. 2014;9: S137–S142)
Thymomas are rare tumors that arise from thymic epithelial cells (TECs) and are associated with many autoimmune 
disorders. The autoimmune disorder most often associated 
with thymoma is myasthenia gravis, which is present in up 
to 30% of patients with thymoma.1 Thymomas tend to release 
immature T-lymphocytes into a systemic circulation, even in 
elderly patients,2,3 which causes some of the immune disorders 
associated with the disease and is a fascinating aspect of thy-
moma biology. In this article, we review some of the immune 
abnormalities in thymoma patients and present current theo-
ries on the underlying mechanisms.
THE ROLE OF THE THYMUS IN THE 
DEVELOPMENT OF THE IMMUNE SYSTEM
A normal thymic architecture is essential for proper 
maturation of thymocytes into functionally competent, self-
tolerant T-cells and elimination of autoreactive T-cells.4 The 
parenchyma of the thymus is compartmentalized into discrete 
cortical and medullary regions. The thymic cortex contains 
densely packed, immature T-cells and cortical TECs (cTECs). 
The thymic medulla is mainly composed of developing T-cells, 
medullary TECs (mTECs), Hassall’s bodies, macrophages, 
and dendritic cells.5 Both cTECs and mTECs are critical for 
proper T-cell development. During normal development, T-cell 
progenitors or thymocytes must pass through the different thy-
mic compartments: the corticomedullary junction, the cortex, 
and the medulla, before exiting from the periphery as normal, 
mature T-lymphocytes. In the thymic cortex, the T-cell pro-
genitors undergo positive selection. During positive selection, 
thymocytes that do not react with major histocompatibility 
complex (MHC) class II are allowed to die. The selected cells 
will be able to function in self–MHC-restricted responses to 
foreign antigens (cells able to react only to antigen presented 
together with MHC class II). Next, the developing T-cells 
undergo negative selection in the thymic medulla, which elim-
inates T-cells that react too strongly with self-antigens.
The major stages of differentiation of T-cell progenitors 
in the thymus are defined by the expression of CD4 and CD8 
molecules on the cell surface. In the initial stage, T-cell pro-
genitors do not express these proteins and are called double 
negative (DN). Subsequently, T-cell progenitors will express 
both molecules becoming double positive (DP). Finally, the 
T-cells will express only one of the molecules, maturing into 
adult T-lymphocytes expressing either CD8 or CD4, and are 
called single positive (SP).
T-cell progenitors gain entry into the thymus via the cor-
ticomedullary junction, which is highly vascularized, as DN 
thymocytes. The DN thymocytes then migrate to the thymic 
cortex to become DP thymocytes, in response to upregulation 
of CD4 and CD8. Self-antigens and peptides inducing CD8+ 
and CD4+ cells are presented to the thymocytes by cTECs 
in a complex process.6–10 During this positive selection pro-
cess, productive engagement of the T-cell receptors on the 
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thymocytes by self-peptide–MHC complexes on the cTECs 
allows survival and differentiation of only the small percent-
age of the DP thymocytes that react with the peptide–MHC 
complexes. The positively selected immature thymocytes then 
become CD8+ or CD4+ SP T-cells. Immature thymocytes 
that fail to interact with self-peptide–MHC complexes die by 
neglect.11
The thymic medulla plays a critical role in the preven-
tion of organ-specific autoimmunity by inducing negative 
selection of SP T-lymphocytes. The thymic medulla contains 
both mTEC and antigen-presenting dendritic cells, and both 
cell types interact with and present tissue-specific self-anti-
gens (TSAs) to the developing T-cells.12 The thymocytes inter-
act with a wide variety of TSAs, and T-cells that react against 
TSAs with high affinity are deleted.
The autoimmune regulator (AIRE) gene controls 
expression of different TSAs in mTECs.13 The expression of 
AIRE occurs late in mTEC differentiation, and the AIRE-
positive mTECs have a fast turnover and eventually suffer cell 
death (apoptosis).14–16 The apoptosis of the mTECs allows the 
release of TSA into thymic dendritic cells, which then present 
the antigen to the developing thymocyte.16
Regulatory T-cells keep autoimmunity in check by sup-
pressing proliferation and function of conventional T-cells. 
Regulatory T-cells function as a “safety net” in the immune 
system. The thymic medulla is essential for the proper devel-
opment of regulatory T-cells.17–19 Regulatory T-cells develop-
ment also include positive selection in the thymic cortex and 
negative selection in the thymic medulla.20
THYMIC MALIGNANCIES AND IMMUNE 
DISORDERS
Thymoma
Thymomas are morphologically heterogeneous tumors 
originating from TECs. Type A thymomas have neoplastic cells 
with spindle- or oval-shaped nuclei and are uniformly bland. 
Type B thymomas resemble the thymic cortex with the pres-
ence of immature lymphocytes. Type AB thymoma combines 
the features of both A and B thymoma.21 A fascinating aspect 
of thymomas is that they generate T-lymphocytes that mature 
into CD4+ and CD8+ lymphocytes.2 Moreover, different thy-
moma types exhibit different patterns of thymopoiesis, and 
type B thymomas produce more lymphocytes than type A.3
Several abnormalities have been described in thymo-
mas that directly affect T-cell development. Because the 
thymic architecture is essential to T-cell maturation and 
development (as discussed previously), it is hardly surpris-
ing that thymomas are intimately associated with a wide 
spectrum of immunological diseases (Table 1). WHo type 
B thymomas are most often associated with immune disor-
ders. Type B thymomas lack medullary features and instead 
contain a disorganized cortex. The neoplastic epithelial cells 
express little or no MHC class II, which is important for pos-
itive selection of T-lymphocytes. Most thymoma neoplastic 
cells also fail to express AIRE,22 an important factor in the 
negative selection of T-lymphocytes. In addition, the produc-
tion of regulatory T-lymphocytes, which protect the body 
from autoimmune processes, is diminished in thymomas. 
Therefore, even though thymomas produce T-lymphocytes, 
positive and negative selection and regulatory T-cell produc-
tion are compromised.
Myasthenia gravis is the most common immune-medi-
ated disease associated with thymoma, and 30% of thymoma 
patients suffer from myasthenia gravis.1,23 Thymoma associ-
ated with myasthenia gravis and myasthenia gravis with-
out thymoma share many common autoantibodies.24,25 In 
TABLE 1.  Autoimmune Disorders Associated with Thymoma
Autoimmune Disorder Frequency
Associated WHO  
Thymoma Type
Neuromuscular
  Myasthenia gravis 30%–44% B1, B2, B3 > AB > A
  (Poly)myositis 1%–5% B1, B2
  Neuromyotonia ~3% B2, B3, AB, TC
  Rippling muscle disease <1% B2
  Morvan’s syndrome <1% B1, B2, B3
  opsomyoclonus <1% B1
  Myocarditis <1% B2, AB
  Dermatomyositis <1% B2
CNS
  Encephalitis <1% A, B1, B2, B3
  Cerebellar degeneration <1% A, AB
Hematological
  Hypo-γ-globulinemia 5%–20% B2 > AB, B1, B3 > A
  Pure red cell aplasia ~4% AB>B2, B1>A, B3
  Agranulocytosis <1% A > others
  Aplastic anemia <1% A, B2
Endocrine
  Hashimoto’s thyroiditis <1% B1, B2
  Grave’s disease <1% B2, likely others
  Addison’s disease <1% B1
  Type I diabetes <1% B1, B2, B3
Cutaneous
  Alopecia areata, totalis 0.5%–17% B1, B2, B3
  Paraneoplastic pemphigus <1% A, AB, likely others
  Pemphigus vulgaris, foliaceus <1% A, AB, likely others
Gastrointestinal
  Colitis <1% A, likely others
  Gastrointestinal dysmotility <1% B1, B3
  Hepatitis <1% B2
Renal
  Minimal change to 
glomerulonephritis
~1% B2 > AB > B3
Systemic
  Lupus erythematosus ~2% B2 > AB, A
  Rheumatoid arthritis <1% B1, B3
  Systemic sclerosis <1% A > AB
  Graft versus host disease <1% A, B2, B3
  Sjogren’s syndrome <1% B1
  Sarcoidosis <1% A, B1
Adapted from Marx et al.24
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particular, there are several parallels between thymoma and 
late-onset myasthenia gravis (myasthenia gravis in patients 
older than 40 years).24,25 Both diseases have a high incidence 
of patients presenting with antistriational antibodies, which 
are antibodies directed against muscle antigens including titin 
and ryanodine receptor. These antibodies are relatively spe-
cific to patients with thymoma,26 and when present in patients 
with early-onset myasthenia gravis have a high predictive 
value for the presence of thymoma.25
other autoantibodies are also common in patients with 
myasthenia gravis and patients with thymoma including anti-
bodies against acetylcholine receptor, cytokines, and interfer-
ons.25 The antibody expression patterns are so similar between 
patients with thymoma and patients with late-onset myasthe-
nia gravis that some have suggested that patients with late-
onset myasthenia gravis may have had a thymoma that was 
rejected.24
Thymic Carcinoma
Thymic carcinomas are rare and comprise a signifi-
cant minority of all thymic epithelial tumors.27 Most studies 
describing the clinical course of patients with thymic carci-
nomas do not describe associated autoimmune disorders.28–32 
Nonetheless, a few studies have described the presence of 
myasthenia gravis in patients with thymic carcinoma,33–35 and 
Yen et al.36 reported an increase in extrathymic cancers in 
patients with thymic neuroendocrine carcinoma, suggesting 
the presence of immune disturbance in the form of defective 
cancer immunosurveillance. However, due to interobserver 
variability in differentiating WHo B3 thymomas from thymic 
carcinomas, it is possible that some patients reported with 
immune disorders and thymic carcinoma actually had WHo 
B3 thymoma.37,38
PROPOSED MECHANISMS EXPLAINING 
IMMUNE DISORDERS IN PATIENTS WITH 
THYMIC MALIGNANCIES
Several mechanisms have been proposed to account for 
immune disorders that develop as a result of thymic malignan-
cies. These include the escape theory, the genetic theory, and 
the AIRE theory.39,40
Escape Theory
The escape theory hypothesizes that immature thy-
moma-derived lymphocytes escape the disorganized tumor 
environment without being subjected to passage through the 
thymic medulla where self-tolerance is induced. The lack of 
medullary passage prevents thymocytes from being exposed 
to tissue-specific antigens released by the mTECs and pre-
sented to the thymocytes by dendritic cells, a process con-
trolled by AIRE (see above).16 Thymomas have been shown to 
have CD4+ T-cells that are less mature than that in the normal 
thymus,41 supporting this theory.
Genetic Theory
This theory hypothesizes that genetic changes in rapidly 
proliferating neoplastic cells (compared with normal TEC) 
impair the development of T-cells, generating self-reactive 
lymphocytes. Thymomas often mimic the thymic cortex, 
where T-lymphocytes undergo positive selection through 
engagement by self-peptide–MHC complexes, which induces 
the survival and differentiation of a small percentage of T-cells. 
Compared with the normal thymic cortical environment, in 
thymomas, this thymic cortexlike environment undergoes 
rapid proliferation, and genetic abnormalities are relatively 
common. Expression of MHCs is impaired affecting positive 
selection. Machens et al.42 demonstrated that in thymomas the 
epithelial cells are genetically different from normal thymic 
cells. Finally, thymocytes from rapidly proliferating cortical 
areas have been demonstrated to be self-reactive.43 Genetic 
abnormalities in thymomas have been extensively studied by 
Girard et al.44 and Badve et al.45
AIRE Theory
As discussed above, AIRE is important for containing 
autoimmunity and is responsible for tissue-specific antigen 
presentation in the thymic medulla, and, as a consequence, is 
also responsible for negative selection of thymocytes. AIRE 
deficiency causes a rare disease called autoimmune polyendo-
crinopathy-candidiasis-ectodermal dystrophy (APECED).46,47 
The first sign of APECED is usually chronic mucocutaneous 
candidiasis, which is likely caused by autoantibodies against 
cytokines, such as interleukin (IL)-17 and IL-22, that cause 
immunodeficiency and enhance susceptibility to Candida 
infection.40,48 APECED patients also produce antibodies 
against other cytokines, such as interferon and IL-12, a finding 
common in patients with thymoma and myasthenia gravis.24 
Finally, APECED patients also have lymphocytic infiltration 
of endocrine glands causing diseases such as diabetes and 
hypoparathyroidism.49,50
The production of anticytokine antibodies by thy-
moma and APECED illustrates a mechanism by which T-cells 
become immunized against AIRE-independent antigens in the 
thymus. TECs do not express interferon, ruling out a defect in 
positive and negative selection of T-cells. However, DCs in the 
thymus express and produce interferon and IL-12.51 The lack 
of expression of interferon by TEC and the expression and 
production by DC is highly suggestive that T-cells are actively 
immunized in the thymus against these molecules. This implies 
that in the AIRE-poor environment a “dangerous” antigenic 
environment exists, e.g., T-cells are easily immunized against 
AIRE-independent antigens present in cells other than TEC or 
antigens present in the extracellular milieu.40 The “dangerous 
antigenic environment” also explains the presence of these 
antibodies in APECED.
Drawing parallels between thymoma and APECED, 
Kisand et al.40 proposed two parallel pathways to explain 
autoimmune disorders in both diseases (Fig. 1). In the 
first pathway, active immunization in the thymus produces 
autoreactive T-cells (autoimmunization). This “dangerous” 
antigenic environment immunizes T-cells against AIRE-
independent antigens, such as antigens cross-reactive with 
skeletal muscle (possibly from myoid cells detected in the 
thymus) and parathyroid (parathyroid tissue is not uncom-
mon in the thymus as both share a common embryological 
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origin). Autoimmunization against cytokines and interferons 
may also occur as there are cytokine-producing and inter-
feron-producing cells in the thymus. This pathway explains 
myasthenia gravis in thymoma patients, parathyroid disease 
in APECED patients, and anticytokine antibodies (includ-
ing immunodeficiency in APECED and in some thymoma 
patients) in both.
In the second proposed pathway, a defective nega-
tive selection process leads to naive, autoreactive cells that 
escape peripheral tolerance mechanisms. This pathway is 
similar to the mechanisms proposed in the escape theory. 
After escaping tolerance mechanisms, these autoreactive 
cells will cause disease, but disease manifestation will take 
more time than with the mechanisms proposed in the auto-
immunization pathway, explaining pemphigus in thymoma 
patients, and thyroid disease and diabetes in APECED 
patients.
Thymomas and Extrathymic Cancers
Souadjian et al.52 was the first to clearly establish the 
association of thymomas and extrathymic cancer, an asso-
ciation confirmed by others.53–55 It is well established that 
the immune system is responsible for eliminating neoplastic 
cells,56 and immunosuppressed patients have higher incidence 
of cancer.57 We previously demonstrated that patients with 
thymoma have a life-long risk of developing extrathymic can-
cers. In a large portion of patients, the extrathymic cancer pre-
ceded the diagnosis of thymoma,55 a finding that challenges 
some of the theories attempting to explain immune disorders 
in patients with thymoma and suggests that there are immune 
phenomena that precede the thymoma itself. Although AIRE 
deficiency may explain some extrathymic cancers in mice,58 it 
is unlikely to explain extrathymic cancers preceding the thy-
moma in man. The thymus in patients with thymoma is not 
AIRE deficient. It is difficult to explain the risk of extrathy-
mic malignancy preceding the thymoma diagnosis, and it may 
represent a fundamental abnormality as in the TECs before 
malignant transformation into thymoma. Also, the thymoma 
itself may be a marker of disturbed thymic environment that 
is producing immunoincompetent T-cells before the thymoma 
itself develops.
CONCLUSIONS
Maturation of thymocytes is a complex process, which 
is still the focus of active investigation. Thymocytes undergo 
positive and negative selection in the thymus in a process 
that is dependent on MHC class II and AIRE, which are 
both lacking in thymoma cells. Current theories explain-
ing immune disorders in patients with thymic malignancies 
seem to be oversimplified, and it is quite likely that a com-
bination of pathways is responsible for different immune 
manifestations. Evidence points firmly toward a combi-
nation of autoimmunization in the thymus and export of 
immature lymphocytes that were not submitted to negative 
selection in the thymus. The presence of extrathymic cancers 
preceding the diagnosis of thymoma raises more questions 
FIGURE 1.  Parallel, coexisting pathways 
proposed to explain autoimmune disorders in 
patients with APECED or thymoma. Left panel, 
In the normal thymus, interaction between 
T-cells and AIRE-dependent TSAs leads to 
destruction of autoreactive cells (negative 
selection). Center panel, Defective negative 
selection. Failure in negative selection gener-
ates autoreactive cells that, with time, escape 
peripheral tolerance mechanisms (anergy 
induction) and engage normal tissue, causing 
autoimmunity. Right panel, Active autoimmu-
nization. T-cells are immunized in the thymus 
(which has become a “dangerous” antigenic 
environment) against local antigens (e.g., 
skeletal muscle antigens, parathyroid tissue, 
cytokines, and interferons). These cells are 
ready for immediate attack and induction of 
antibody response. Reproduced with permis-
sion from Kisand et al.40
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than answers and may imply a more basic defect in the TECs 
of which thymoma is a marker. More investigation into the 
basic mechanisms of induced autoimmunity in thymomas is 
needed for a full understanding of the disease and the mech-
anisms causing it.
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